Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Haleon PLC ( (GB:HLN) ) has provided an announcement.
Haleon PLC has announced significant changes in its board and committee leadership, with Alan Stewart set to become the Senior Independent Director, succeeding Vindi Banga, who will assume the role of Chair effective January 1, 2026. These changes are aligned with the UK Corporate Governance Code 2024, and Vindi Banga’s remuneration as Chair will be £757,103 per annum, as previously disclosed. These leadership adjustments are expected to influence Haleon’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £370.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects strong financial performance and positive corporate events, which are the most significant factors. Technical analysis and valuation present a more mixed outlook, with some short-term challenges. The earnings call highlights regional strengths but also points to challenges in North America. Overall, the company is well-positioned for future growth, but careful management of liabilities and strategic initiatives will be crucial.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse range of products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 21,476,311
Technical Sentiment Signal: Hold
Current Market Cap: £31.93B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.